Why the study?
PMBV is established for symptomatic moderate or severe rheumatic mitral valve disease, but is not preferred in MS with moderate MR due to the risk of severe MR.
Does percutaneous mitral balloon valvuloplasty have acceptable safety and feasibility in symptomatic mitral stenosis patients with moderate mitral regurgitation compared to those with mild or no mitral regurgitation?
Observational
No
Does percutaneous mitral balloon valvuloplasty have acceptable safety and feasibility in symptomatic mitral stenosis patients with moderate mitral regurgitation compared to those with mild or no mitral regurgitation?
Answers are grounded in this paper and cite their sources.
PMBV appears comparably safe in selected MS patients with moderate MR; leaves open whether it warrants broader use pending larger trials.
Objective: Rheumatic heart disease is the deposition of immune complexes which cause malfunction of the heart valves. Percutaneous mitral balloon valvuloplasty (PMBV) is an established treatment option in patients with symptomatic moderate or severe rheumatic mitral valve disease, but PMBV is not a preferred option in mitral stenosis (MS) patients with moderate mitral regurgitation (MR) due to the risk of severe MR. The aim of this study was to evaluate the safety and feasibility of PMBV in symptomatic MS patients with moderate MR by comparing the post-procedural parameters with those of MS patients with mild or no MR.
No takes yet. Share an insight, caveat, or question.
Çelik et al. (2020) conducted an observational in Symptomatic mitral stenosis. Percutaneous mitral balloon valvuloplasty vs. Mitral stenosis patients with mild or no mitral regurgitation was evaluated on Safety and feasibility (post-procedural parameters).
Synapse has enriched 10 related papers. Consider them for comparative context: